Email this article Current management options for rosacea: clear skin is our reality
- Authors: Olisova O.Y.1, Anpilogova E.M.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 23, No 5 (2020)
- Pages: 324-333
- Section: CLINICAL PICTURE, DIAGNOSIS, AND THERAPY OF DERMATOSES
- URL: https://rjsvd.com/1560-9588/article/view/49867
- DOI: https://doi.org/10.17816/dv49867
- ID: 49867
Cite item
Open Access
Access granted
Abstract
BACKGROUND: Treatment of rosacea makes enough difficulties. Review of current etiology, pathogenesis and social burden of rosacea are presented, as well as results of international studies on efficacy of brimonidine gel (Mirvaso Derm) and ivermectin creme (Soolantra) usage in erytemato-teleangiectatic and papulopustular rosacea.
AIMS: To evaluate efficacy and safety of topical ivermectin and brimonidine for the treatment of rosacea.
MATERIALS AND METODS: Results of our own experience of using these drugs in 87 rosacea patients are presented. Depending on the subtype and severity of the disease, patients with erythematotelangiectatic subtype rosacea were treated with Mirvaso Derm gel (59%), Soolantra cream, and tacrolimus ointment (41%); doxycycline 0.1–0.2 g twice a day and Soolantra cream (29%); and minocycline 0.05–0.1 g a day and Soolantra cream (37%).
Moreover, patients with papulopustular subtype rosacea were treated with the following combined therapy: doxycycline/minocycline + Mirvaso Derm gel + Soolantra cream (34%). Regardless of the severity of the process, all patients received Cetaphil Pro for redness prone skin (Cetaphil Redness Control line until 2018) as daily skin care products. The mean duration time of therapy for antibiotics was 1.5–2 month and topical therapy had a relatively longer duration time of therapy: from 8 to 24 months for Mirvaso Derm and 3 to 10 months for Soolantra.
RESULTS: After the therapy 43 and 55% of patients with papulopustular rosacea achieved Investigator Global Assessment (IGA) scores of 0 (clear) and 1 (almost clear), respectively; and 41% and 50% of patients with erythemato-telangiectatic rosacea achieved IGA scores 0 and 1, respectively. During the 1-year follow-up ‘clear and almost clear skin’ (IGA = 0–1) remained in 87% of patients with papulopustular subtype rosacea and 79% of patients with erythemato-telangiectatic subtype rosacea.
CONCLUSION: Thus, based on the results, Mirvaso Derm gel and Soolantra creme have demonstrated to be very effective and safe options for rosacea treatment.
Keywords
Full Text
About the authors
Olga Yu. Olisova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: olisovaolga@mail.ru
ORCID iD: 0000-0003-2482-1754
MD, PhD, DSc., Head of Department
Russian Federation, MoscowE. M. Anpilogova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: olisovaolga@mail.ru
ORCID iD: 0000-0001-9478-5838
Russian Federation, Moscow
References
- Olisova OYu, Dodina MI, Kushlinskiy NE. The role of vascular endothelial growth factor in rosacea pathogenesis and it’s medical correction. Russian Journal of Clinical Dermatology and Venereology. 2012;10(1):49-55. (in Russian)
- Alexis A, Callender V, Baldwin H, Desai S, Rendon M, Taylor S. Global epidemiology and clinical spectrum of rosacea, highlighting skin of color: Review and clinical practice experience. J Am Acad Dermatol. 2019;80(6):1722-9.e7. doi: 10.1016/j.jaad.2018.08.049.
- Two A, Wu W, Gallo R, Hata T. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72(5):749-58. doi: 10.1016/j.jaad.2014.08.028.
- Moran E, Foley R, Powell F. Demodex and rosacea revisited. Clin Dermatol. 2017;35(2):195-200. doi: 10.1016/j.clindermatol.2016.10.014.
- Olisova OYu, Vladimirova EV, Babushkin AM. The skin and the sun. Russian Journal of Skin and Venereal Diseases. 2012;15(6):57-62. (in Russian)
- Ahn C, Huang W. Rosacea Pathogenesis. Dermatol Clin. 2018;36(2):81-6. doi: 10.1016/j.det.2017.11.001.
- Tan J, Steinhof M, Bewley A, Gieler U. Rosacea: Beyond the Visible. The BMJ Hosted Content 2018. Available at: http://hosted.bmj.com/rosaceabeyondthevisible. Data accessed: Oct 2020.
- Steinhof M, Harper J, Gieler U, Tan J. Beyond the visible: rosaea and psoriasis of the face. The BMJ Hosted Content. 2018. Available at: http://hosted.bmj.com/rosaceabeyondthevisible. Accessed: Oct 2020.
- Webster G, Schaller M, Tan J, Jackson J, Kerrouche N, Schafer G. Defining treatment success in rosacea as ‘clear’ may provide multiple patient benefits: results of a pooled analysis. J Dermatolog Treat. 2017;28(5):469-74. doi: 10.1080/09546634.2017.1343435.
- Asai Y, Tan J, Baibergenova A, Barankin B, Cochrane C, Humphrey S, et al. Canadian clinical practice guidelines for Rosacea. J Cutan Med Surg. 2016;20(5):432-45.
- Anzengruber F, Czernielewski J, Conrad C, Feldmeyer L, Yawalkar N, Hausermann P, et al. Swiss S1 guideline for the treatment of rosacea. J Eur Acad Dermatol Venereol. 2017;31(11):1775-91.
- Schaller M, Almeida L, Bewley A, Cribier B, Dlova N, Kautz G, et al. Rosacea treatment update: recommendations from the global ROSacea Consensus (ROSCO) panel. Br J Dermatol. 2017;176(2):465-71.
- Russian society of dermatovenereologists and cosmetologists. Clinical guideline 2020. Rosacea. Available at: https://cnikvi.ru/docs/clinic_recs/klinicheskie-rekomendatsii-2019-2020/. Accessed October 2020. (in Russian)
- Bertino B, Blanchet-Rethore S, Thibaut de Menonville S, Reynier P, Mehul B, Bogouch A, et al. Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function. Exp Dermatol. 2018;27(12):1378-87. doi: 10.1111/exd.13793.
- Fowler J, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650-6.
- Moore A, Kempers S, Murakawa G, Weiss J, Tauscher A, Swinyer L, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13(1):56-61.
- Del Rosso J. Topical Ivermectin: Data Supporting Dual Modes of Action in Rosacea. J Clin Aesthet Dermatol. 2017;10(9):39-42.
- Formiga F, Leblanc R, de Souza Reboucas J, Farias L, de Oliveira R, Pena L. Ivermectin: an award-winning drug with expected antiviral activity against COVID-19. J Control Release. 2020;S0168-3659(20)30580-0. doi: 10.1016/j.jconrel.2020.10.009.
- Dall’Oglio F, Lacarrubba F, Luca M, Boscaglia S, Micali G. Clinical and erythema-Directed imaging evaluation of Papulo-Pustular rosacea with topical ivermectin: A 32 weeks duration study. J Dermatol Treat. 2019;30(7):703-7. doi: 10.1080/09546634.2019.1572860.
- Trave I, Merlo G, Cozzani E, Parodi A. Real-life experience on effectiveness and tolerability of topical ivermectin in papulopustular rosacea and antiparasitic effect on Demodex mites. Dermatol Ther. 2019;32(6):e13093. doi: 10.1111/dth.13093.
- Sobolewska B, Doycheva D, Deuter C, Schaller M, Zierhut M. Efficacy of Topical Ivermectin for the Treatment of Cutaneous and Ocular Rosacea. Ocul Immunol Inflamm. 2020:1-5. doi: 10.1080/09273948.2020.1727531.
- Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316-23.
- Taieb A, Ortonne J, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone M, Jacovella J. Ivermectin Phase III study group. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103-10. doi: 10.1111/bjd.13408.
- Taieb A, Khemis A, Ruzicka T, Baranska-Rybak W, Berth-Jones J, Schauber J, et al. Ivermectin Phase III Study Group. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. J Eur Acad Dermatol Venereol. 2016;30(5):829-36.
- Gold L, Papp K, Lynde C, Lain E, Gooderham M, Johnson S, Kerrouche N. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study. J Drugs Dermatol. 2017;16(9):909-16.
- Schaller M, Kemeny L, Havlickova B, Jackson J, Ambroziak M, Lynde C, et al. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea. J Am Acad Dermatol. 2020;82(2):336-43. doi: 10.1016/j.jaad.2019.05.063.
Supplementary files
